Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA)

Journal of Clinical Microbiology

Volumn 42, Issue 2, 2004, Pages 563-569

  Elbeik, Tarek ^a,b   Surtihadi, Johan ^c   Destree, Mark ^f,i   Gorlin, Jed ^f   Holodniy, Mark ^d   Jortani, Saeed A ^g   Kuramoto, Ken ^e,j   Ng, Valerie ^a,b   Valdes Jr , Roland ^g   Valsamakis, Alexandra ^h   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c BAYER CORPORATION   (United States)

^d STANFORD UNIVERSITY   (United States)

^e BloodSource   (United States)

^f Memorial Blood Centers of Minnesota   (United States)

^g University of Louisville School of Medicine   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ Roche Diagnostics Corporation   (United States)

^j XDx Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; EDETIC ACID; VIRUS RNA;

ANALYTIC METHOD; ARTICLE; BLOOD DONOR; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; EVALUATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; LINEAR SYSTEM; MOLECULAR CLONING; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; RNA ANALYSIS; RNA TRANSCRIPTION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARD; STANDARDIZATION;

BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; HEPACIVIRUS; HEPATITIS C; HUMANS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING;

HEPATITIS C VIRUS; STAPHYLOCOCCUS PHAGE 3A;

EID: 10744231244     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.2.563-569.2004     Document Type: Article

References (27)

1. Alter, M. J., D. Kruszon-Moran, O. V. Nainan, G. M. McQuillan, F. Gao, L. A. Moyer, R. A. Kaslow, and H. S. Margolis. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:556-562.
2. Beld, M., R. Sentjens, S. Rebers, C. Weegink, J. Weel, C. Sol, and R. Boom. 2002. Performance of the new Bayer VERSANT HCV RNA 2.0 Assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, version 2.0, Assay. J. Clin. Microbiol. 40:788-793.
3. Carithers, R. L., and S. S. Emerson. 1997. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 26(Suppl.):83S-88S.
4. Collins, M. L., B. Irvine, D. Tyner, E. Fine, C. Zayati, C.-A. Chang, T. Horn, D. Ahle, J. Detmer, L.-P. Shen, J. Kolberg, S. Bushnell, M. S. Urdea, and D. D. Ho. 1997. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/mL. Nucleic Acids Res. 25:2979-2984.
5. Collins, M. L., C. Zayati, J. J. Detmer, B. Daly, J. A. Kolberg, T.-A. Cha, B. D. Irvine, J. Tucker, and M. S. Urdea. 1995. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal. Biochem. 226:120-129.
6. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M.-H. Ling, and J. Albrecht for the International Hepatitis Interventional Therapy Group. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1493-1499.
7. Detmer, J., R. Lagier, J. Flynn, C. Zayati, J. Kolberg, M. Collins, M. Urdea, and R. Sanchez-Pescador. 1996. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes using branched-DNA technology. J. Clin. Microbiol. 34:901-907.
8. Elbeik, T., R. Delassandro, Y.-M. A. Chen, S. V. Soutchkov, R. A. Loftus, and S. Beringer. 2003. Global cost modeling analysis of HIV-1 and HCV viral load assays. Expert Rev. Phamacoecon. Outcomes Res. 3:383-407.
9. Elbeik, T., R. A. Loftus, and S. Beringer. 2002. Health care industries perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay. Expert Rev. Mol. Diagn. 2:275-285.
10. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Gonçales, D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
11. Germer, J. J., P. J. Heimgartner, D. M. Ilstrup, W. S. Harmsen, G. D. Jenkins, and R. Patel. 2002. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:495-500.
12. Hodinka, R. L. 1998. The clinical utility of viral quantitation using molecular methods. Clin. Diagn. Virol. 10:25-47.
13. Hoofnagle, J. H. 1997. Hepatitis C: the clinical spectrum of disease. Hepatology 26(Suppl. 1):15S-20S.
14. Lee, S. S., E. J. Heathcote, K. R. Reddy, S. Zeuzem, M. W. Fried, T. L. Wright, P. J. Pockros, D. Häussinger, C. I. Smith, A. Lin, and S. C. Pappas. 2002. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J. Hepatol. 37:500-506.
15. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M.-H. Ling, J. K. Albrecht, and the International Hepatitis Interventional Therapy Group. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
16. National Center for Health Statistics. 1996. National Health and Nutrition Examination Survey (NHANES) III. 1988-94. [Online.] http://www.cdc.gov/nohs/about/major/nhanes/datalink.htm#NHANESIII.
17. Pawlotsky, J.-M. 2002. Use and interpretation of virological tests for hepatitis C. Hepatology 36(Suppl. 1):S65-S73.
18. Pawlotsky, J.-M., M. Bouvier-Alias, C. Herzode, F. Darthuy, J. Remire, and D. Dhumeaux. 2000. Standardization of hepatitis C virus RNA quantification. Hepatology 32:654-659.
19. Poynard, T., J. McHutchison, Z. Goodman, M.-H. Ling, and J. Albrecht for the ALGOVIRC Project Group. 2000. Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31:211-218.
20. Ross, R. S., S. Viazov, S. Sarr, S. Hoffmann, A. Kramer, and M. Roggendorf. 2002. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J. Virol. Methods 101:159-168.
21. Saldanha, J., N. Lelie, A. Heath, and the WHO Collaborative Study Group. 1999. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang. 76:149-158.
22. Saldanha, J., A. Heath, N. Lelie, G. Pisani, M. Nühling, M. Yu, and the Collaborative Study Group. 2000. Calibration of HCV working reagents for NAT assays against the HCV international standard. Vox Sang. 78:217-224.
23. Seeff, L. B., and J. H. Hoofnagle. 2003. Appendix: the National Institutes of Health consensus development conference management of hepatitis C 2002. Clin. Liver Dis. 7:261-287.
24. Sherman, K. E., S. D. Rouster, and P. S. Horn. 2002. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin. Infect. Dis. 35:482-487.
25. Trimoulet, P., P. Halfon, E. Pohier, H. Khiri, G. Chêne, and H. Fleury. 2002. Evaluation of the VERSANT HCV RNA 3.0 Assay for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:2031-2036.
26. World Health Organization. October 2000, revision date. Fact sheet no. 164: hepatitis C. [Online.] http://who.int/inf-fs/en/fact164.html.
27. Zeuzem, S., S. V. Feinman, J. Rasenack, E. J. Heathcote, M.-Y. Lai, E. Gane, J. O'Grady, J. Reichen, M. Diago, A. Liu, J. Hoffman, and M. J. Brunda. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343:1666-1672.